Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in a better direction by brewing cups of stimulation. Our choice today is pistachio. Please feel free to join us. Meanwhile, here are a few items of interest to start you on your journey, which we hope is meaningful and productive. Best of luck, and do keep in touch. … During July and August 2025, approximately one in 10 U.S. adults reported taking a GLP-1 medication during the previous year, according to a report from the Centers for Disease Control and Prevention. Among GLP-1 users, approximately one in five reported taking a compounded version and 9% of those taking a GLP-1 medicine were uncertain whether it was compounded, suggesting difficulties in distinguishing compounded versions from medicines approved by the U.S. Food and Drug Administration. Approximately two in five GLP-1 users modified their use of the medication from the way it was prescribed, often citing cost and availability as barriers to prescribed use. The pharmaceutical industry wants an audit of how the World Health Organization is spending millions of dollars that drugmakers contribute to a program designed to prepare the world for the next flu pandemic, Devex reports. The International Federation of Pharmaceutical Manufacturers is pushing for one of the so-called Big 4 accounting firms to audit industry contributions to the WHO’s Pandemic IInfluenza Preparedness Framework, citing concerns over how the funds are used. Some manufacturers are even withholding funds. However, the WHO says it already has an external auditor and that it spends all funds in accordance with its rules. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe
STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.